| Biological Sciences | 2021-2025 | 685 | IN 15 | 99.27 |
| Molecular Medicine | Lifetime | 95 | IN 3 | 97.79 |
| Food Science and Technology | Lifetime | 803 | IN 21 | 97.05 |
| Endocrinology | Lifetime | 236 | IN 4 | 96.16 |
| Applied Microbiology and Biotechnology | Lifetime | 132 | IN 3 | 92.36 |
| Clinical Biochemistry | Lifetime | 729 | IN 6 | 83.52 |
| Molecular Medicine | 2021-2025 | 18 | IN 1 | 98.67 |
| Epidemiology | 2021-2025 | 274 | IN 4 | 97.79 |
| Endocrinology | 2021-2025 | 49 | IN 1 | 90.05 |
| Food Science and Technology | 2021-2025 | 402 | IN 20 | 92.17 |
| Infectious Diseases | 2021-2025 | 519 | IN 8 | 88.98 |
| Antibiotic Resistance in Bacteria | Lifetime | 235 | IN 2 | 99.14 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 329 | IN 2 | 98.35 |
| Antibiotic Use and Resistance | Lifetime | 225 | IN 1 | 98.41 |
| Vibrio bacteria research studies | Lifetime | 265 | IN 8 | 98.00 |
| Pneumonia and Respiratory Infections | Lifetime | 595 | IN 4 | 98.04 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 377 | IN 1 | 97.99 |
| Salmonella and Campylobacter epidemiology | Lifetime | 395 | IN 7 | 97.74 |
| Infections and bacterial resistance | Lifetime | 76 | IN 1 | 96.49 |
| Urinary Tract Infections Management | Lifetime | 728 | IN 3 | 95.92 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 996 | IN 16 | 95.61 |
| Burkholderia infections and melioidosis | Lifetime | 169 | IN 2 | 91.48 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 698 | IN 7 | 86.44 |
| Diphtheria, Corynebacterium, and Tetanus | Lifetime | 653 | IN 6 | 82.32 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 742 | IN 18 | 68.70 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 25 | IN 1 | 99.49 |
| Pneumonia and Respiratory Infections | 2021-2025 | 36 | IN 1 | 98.81 |
| Vibrio bacteria research studies | 2021-2025 | 18 | IN 2 | 97.29 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 35 | IN 1 | 98.55 |
| Salmonella and Campylobacter epidemiology | 2021-2025 | 31 | IN 1 | 97.55 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 53 | IN 1 | 97.42 |
| Antibiotic Use and Resistance | 2021-2025 | 118 | IN 1 | 96.73 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 98 | IN 1 | 95.55 |
| vaccines and immunoinformatics approaches | 2021-2025 | 289 | IN 33 | 87.86 |
| Bacterial Infections and Vaccines | 2021-2025 | 250 | IN 2 | 87.47 |
| Streptococcal Infections and Treatments | 2021-2025 | 374 | IN 4 | 85.67 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 478 | IN 17 | 85.46 |
| Nephrotoxicity and Medicinal Plants | 2021-2025 | 52 | IN 2 | 73.39 |
| Infections and bacterial resistance | 2021-2025 | 154 | IN 9 | 69.24 |
| Diphtheria, Corynebacterium, and Tetanus | 2021-2025 | 88 | IN 2 | 69.28 |
| Burkholderia infections and melioidosis | 2021-2025 | 576 | IN 49 | 29.01 |